Literature DB >> 9169945

Prolonged use of propranolol safely decreases cardiac work in burned children.

P W Baron1, R E Barrow, E J Pierre, D N Herndon.   

Abstract

Propranolol has been shown to be effective for as long as 5 days in massively burned children to reduce heart rate and cardiac work. This article describes the use of propranolol given for 10 days to burned children to test whether the drug remains effective and safe in reducing heart rate and cardiac work for longer periods. We prospectively studied 22 children, 1 to 10 years of age with burns covering > or = 40% of their total body surface area. These children were treated with 0.5 to 1.0 mg/kg propranolol given orally or intravenously every 8 hours for 10 days. In both septic and nonseptic patients, propranolol significantly decreased their daily average heart rate (between 10% and 13%, p < 0.05) and rate-pressure product (between 10% and 16%, p < 0.05) compared with their 24-hour mean before propranolol treatment. No significant change in mean arterial blood pressure, or plasma urea nitrogen creatinine or glucose levels could be shown. No hypotension, hypothermia, azotemia, hyperglycemia or hypoglycemia, arrhythmia, bronchospasm, or peripheral ischemia was noted during or after treatment. Whereas propranolol lowered heart rate more per milligram per kilogram body weight when given intravenously, both routes were safe and effective. From these data, we conclude that propranolol can be given to decrease the work of the heart safely and effectively for > or = 10 days.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169945     DOI: 10.1097/00004630-199705000-00008

Source DB:  PubMed          Journal:  J Burn Care Rehabil        ISSN: 0273-8481


  37 in total

1.  Reversal of Growth Arrest With the Combined Administration of Oxandrolone and Propranolol in Severely Burned Children.

Authors:  David N Herndon; Charles D Voigt; Karel D Capek; Paul Wurzer; Ashley Guillory; Andrea Kline; Clark R Andersen; Gordon L Klein; Ronald G Tompkins; Oscar E Suman; Celeste C Finnerty; Walter J Meyer; Linda E Sousse
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

2.  The use of beta-adrenergic blockade in preventing trauma-induced hepatomegaly.

Authors:  Robert E Barrow; Robert R Wolfe; Mohan R Dasu; Laura N Barrow; David N Herndon
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

3.  Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants.

Authors:  Giovanni Frongia; Ji-Oun Byeon; Raoul Arnold; Arianeb Mehrabi; Patrick Günther
Journal:  World J Pediatr       Date:  2018-05-23       Impact factor: 2.764

Review 4.  Early Enteral Nutrition for Burn Injury.

Authors:  Samuel P Mandell; Nicole S Gibran
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-01-01       Impact factor: 4.730

5.  The Safety and Efficacy of Propranolol in Reducing the Hypermetabolic Response in the Pediatric Burn Population.

Authors:  Sylvia Ojeda; Emily Blumenthal; Pamela Stevens; Clark R Andersen; Lucy Robles; David N Herndon; Walter J Meyer
Journal:  J Burn Care Res       Date:  2018-10-23       Impact factor: 1.845

6.  Beta blockade: the right time, the right dose, the right receptor!

Authors:  Ahmed M Al-Mousawi; Marc G Jeschke; David N Herndon
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

Review 7.  The hepatic response to thermal injury: is the liver important for postburn outcomes?

Authors:  Marc G Jeschke
Journal:  Mol Med       Date:  2009-04-10       Impact factor: 6.354

Review 8.  Alcohol Modulation of the Postburn Hepatic Response.

Authors:  Michael M Chen; Stewart R Carter; Brenda J Curtis; Eileen B O'Halloran; Richard L Gamelli; Elizabeth J Kovacs
Journal:  J Burn Care Res       Date:  2017 Jan/Feb       Impact factor: 1.845

Review 9.  Is propranolol of benefit in pediatric burn patients?

Authors:  Celeste C Finnerty; David N Herndon
Journal:  Adv Surg       Date:  2013

Review 10.  Bench-to-bedside review: Burn-induced cerebral inflammation--a neglected entity?

Authors:  Michael A Flierl; Philip F Stahel; Basel M Touban; Kathryn M Beauchamp; Steven J Morgan; Wade R Smith; Kyros R Ipaktchi
Journal:  Crit Care       Date:  2009-06-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.